Basic information Safety Supplier Related

Foralumab

Basic information Safety Supplier Related

Foralumab Basic information

Product Name:
Foralumab
Synonyms:
  • Foralumab
  • Research Grade Foralumab(DHC27705)
  • Research Grade Foralumab
  • Foralumab (anti-CD3E)
CAS:
946415-64-1
MW:
0
Mol File:
Mol File
More
Less

Foralumab Chemical Properties

form 
Liquid
color 
Colorless to light yellow
More
Less

Foralumab Usage And Synthesis

Uses

Foralumab (NI-0401) is a potent, orally active human monoclonal antibody targeting the CD3. Foralumab modulates immune responses by human cells in NSG mice that were reconstituted with human hematopoietic stem cells[1].

in vivo

Foralumab (NI-0401; 0.6-250 μg; p.o.; daily, for 5 d) delays the rejection of B6Rag2?/? skin grafted onto the humanized mice[1].
Foralumab (0.6-250 μg; p.o. and i.h.; daily, for 5 d) prevents skin xenograft rejection in mice with human immune systems[1].
Foralumab (1-15 μg; p.o.; daily, for 5 d) has good bioavailability of intragastric in humanized mice[1].

Animal Model:Humanized NOD/SCID IL-2γc?/? mice with Skin grafts (Humanized mice: CD34+ cells are injected intra-hepatically into irradiated (0.9 Gy) NSG pups within 48 hours of birth) [1]
Dosage:15 μg
Administration:Oral administration; daily, for 5 days and weekly dosing
Result:Showed robust protection against graft rejection and prolongs graft survival.
Reduced proliferation of CD8+ T cells and reduced release of TNF.
Increased the concentration of IL-10.
Animal Model:Humanized NOD/SCID IL-2γc?/? mice with Skin grafts (Humanized mice: CD34+ cells are injected intra-hepatically into irradiated (0.9 Gy) NSG pups within 48 hours of birth) [1]
Dosage:1, 5, 15, 50, and 250 μg (p.o.), 0.6 mg/kg (i.h.)
Administration:Oral administration and subcutaneous injection; daily, for 5 days and weekly dosing
Result:Had tolerant to autologous skin grafts in humanized mice.
Animal Model:Humanized NOD/SCID IL-2γc?/? mice with Skin grafts (Humanized mice: CD34+ cells are injected intra-hepatically into irradiated (0.9 Gy) NSG pups within 48 hours of birth) [1]
Dosage:0, 5, 10, and 15 μg
Administration:Oral administration and subcutaneous injection; daily, for 5 days and weekly dosing
Result:Increased human Ig on the surface of CD4+ and CD8+ T cells.
Had free mAb in the serum of mice

References

[1] Ogura M, et, al. Oral treatment with foralumab, a fully human anti-CD3 monoclonal antibody, prevents skin xenograft rejection in humanized mice. Clin Immunol. 2017 Oct;183:240-246. DOI:10.1016/j.clim.2017.07.005

ForalumabSupplier

Shanghai YuanYe Biotechnology Co., Ltd.
Tel
021-61312847; 18021002903
Email
3008007409@qq.com
ShangHai Biochempartner Co.,Ltd
Tel
177-54423994 17754423994
Email
2853530910@QQ.com
Guangzhou Hongyuan Chemical Co.,Ltd
Tel
15817493340
Email
981810490@qq.com
Wuhan Chemstan Biotechnology Co., Ltd.
Tel
027-65317797 15926423062
Email
422450190@qq.com
TargetMol Chemicals Inc.
Tel
4008200310
Email
marketing@tsbiochem.com